Neuro-Sys, a company that deals with pharmacological Contract Research Services specialising in the R&D and in vitro testing of molecules used to treat neurogenerative diseases in the Central Nervous System and Peripheral Nervous System, has launched its in vivo services, it was reported on Tuesday.
The investment is intended to enable the company to provide animal models and behavioural testing that uses digital tracking systems for the testing of candidate molecules, to its present in vitro, and to new customers.
Chief scientific officer, Noelle Callizot, said, 'We continue to conduct research to refine our knowledge of the pathological pathways and to develop our innovative in vitro models. At the same time, it's important that our in vivo activity validates and enhances our in vitro work, allowing our customers a seamless process in their drug development programmes.'
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference